NYSE:RDY

Dr. Reddy's Laboratories Competitors

$72.20
+1.18 (+1.66 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$71.80
$72.56
50-Day Range
$59.01
$71.02
52-Week Range
$48.56
$73.50
Volume70,089 shs
Average Volume197,124 shs
Market Capitalization$12.01 billion
P/E Ratio59.67
Dividend Yield0.38%
Beta0.41

Competitors

Dr. Reddy's Laboratories (NYSE:RDY) Vs. ALXN, BGNE, RPRX, GMAB, CVAC, and HZNP

Should you be buying RDY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Dr. Reddy's Laboratories, including Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Royalty Pharma (RPRX), Genmab A/S (GMAB), CureVac (CVAC), and Horizon Therapeutics Public (HZNP).

Alexion Pharmaceuticals (NASDAQ:ALXN) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Alexion Pharmaceuticals and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Dr. Reddy's Laboratories8.23%16.33%10.79%

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Dr. Reddy's Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.61$2.40 billion$9.7417.64
Dr. Reddy's Laboratories$2.32 billion5.18$259 million$2.7925.88

Alexion Pharmaceuticals has higher revenue and earnings than Dr. Reddy's Laboratories. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Alexion Pharmaceuticals and Dr. Reddy's Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals015402.21
Dr. Reddy's Laboratories00303.00

Alexion Pharmaceuticals presently has a consensus price target of $159.3158, indicating a potential downside of 7.27%. Dr. Reddy's Laboratories has a consensus price target of $70.00, indicating a potential downside of 3.05%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Alexion Pharmaceuticals.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Dr. Reddy's Laboratories on 11 of the 14 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares Dr. Reddy's Laboratories and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
BeiGene-569.22%-56.81%-39.93%

Insider & Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Dr. Reddy's Laboratories and BeiGene's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion5.18$259 million$2.7925.88
BeiGene$428.21 million64.96$-948,630,000.00($15.80)-19.20

Dr. Reddy's Laboratories has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Dr. Reddy's Laboratories has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Dr. Reddy's Laboratories and BeiGene, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00303.00
BeiGene21602.44

Dr. Reddy's Laboratories presently has a consensus price target of $70.00, suggesting a potential downside of 3.05%. BeiGene has a consensus price target of $317.1250, suggesting a potential upside of 4.55%. Given BeiGene's higher possible upside, analysts clearly believe BeiGene is more favorable than Dr. Reddy's Laboratories.

Summary

Dr. Reddy's Laboratories beats BeiGene on 8 of the 14 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Dr. Reddy's Laboratories and Royalty Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00303.00
Royalty Pharma05402.44

Dr. Reddy's Laboratories presently has a consensus price target of $70.00, suggesting a potential downside of 3.05%. Royalty Pharma has a consensus price target of $51.8750, suggesting a potential upside of 25.03%. Given Royalty Pharma's higher possible upside, analysts clearly believe Royalty Pharma is more favorable than Dr. Reddy's Laboratories.

Profitability

This table compares Dr. Reddy's Laboratories and Royalty Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
Royalty PharmaN/AN/AN/A

Dividends

Dr. Reddy's Laboratories pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Dr. Reddy's Laboratories pays out 9.7% of its earnings in the form of a dividend. Royalty Pharma has raised its dividend for 1 consecutive years. Royalty Pharma is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Earnings & Valuation

This table compares Dr. Reddy's Laboratories and Royalty Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion5.18$259 million$2.7925.88
Royalty PharmaN/AN/AN/AN/AN/A

Dr. Reddy's Laboratories has higher revenue and earnings than Royalty Pharma.

Institutional and Insider Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 40.9% of Royalty Pharma shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 2.5% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Royalty Pharma beats Dr. Reddy's Laboratories on 7 of the 12 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Genmab A/S and Dr. Reddy's Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genmab A/S24902.47
Dr. Reddy's Laboratories00303.00

Genmab A/S presently has a consensus price target of $41.5714, suggesting a potential upside of 11.63%. Dr. Reddy's Laboratories has a consensus price target of $70.00, suggesting a potential downside of 3.05%. Given Genmab A/S's higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than Dr. Reddy's Laboratories.

Insider and Institutional Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Genmab A/S and Dr. Reddy's Laboratories' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$804.57 million30.36$324.68 million$0.5173.02
Dr. Reddy's Laboratories$2.32 billion5.18$259 million$2.7925.88

Genmab A/S has higher earnings, but lower revenue than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Genmab A/S and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genmab A/S50.99%34.40%30.67%
Dr. Reddy's Laboratories8.23%16.33%10.79%

Volatility & Risk

Genmab A/S has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Summary

Genmab A/S beats Dr. Reddy's Laboratories on 8 of the 14 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and CureVac (NASDAQ:CVAC) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings for Dr. Reddy's Laboratories and CureVac, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00303.00
CureVac11302.40

Dr. Reddy's Laboratories currently has a consensus target price of $70.00, suggesting a potential downside of 3.05%. CureVac has a consensus target price of $58.3333, suggesting a potential downside of 44.86%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than CureVac.

Earnings and Valuation

This table compares Dr. Reddy's Laboratories and CureVac's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion5.18$259 million$2.7925.88
CureVacN/AN/AN/AN/AN/A

Dr. Reddy's Laboratories has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 4.3% of CureVac shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Dr. Reddy's Laboratories and CureVac's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
CureVacN/AN/AN/A

Summary

Dr. Reddy's Laboratories beats CureVac on 8 of the 8 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Horizon Therapeutics Public (NASDAQ:HZNP) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Dr. Reddy's Laboratories and Horizon Therapeutics Public, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00303.00
Horizon Therapeutics Public001103.00

Dr. Reddy's Laboratories currently has a consensus target price of $70.00, suggesting a potential downside of 3.05%. Horizon Therapeutics Public has a consensus target price of $111.3636, suggesting a potential upside of 29.13%. Given Horizon Therapeutics Public's higher possible upside, analysts clearly believe Horizon Therapeutics Public is more favorable than Dr. Reddy's Laboratories.

Earnings & Valuation

This table compares Dr. Reddy's Laboratories and Horizon Therapeutics Public's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion5.18$259 million$2.7925.88
Horizon Therapeutics Public$1.30 billion14.91$573.02 million$1.9444.45

Horizon Therapeutics Public has lower revenue, but higher earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Dr. Reddy's Laboratories and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
Horizon Therapeutics Public43.55%25.66%14.19%

Risk & Volatility

Dr. Reddy's Laboratories has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Dr. Reddy's Laboratories on 10 of the 13 factors compared between the two stocks.


Dr. Reddy's Laboratories Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$171.81+0.8%$37.97 billion$4.99 billion40.14Analyst Revision
BeiGene logo
BGNE
BeiGene
1.3$303.32+2.9%$27.81 billion$428.21 million-15.01Earnings Announcement
Analyst Report
Analyst Revision
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$41.49+1.3%$25.19 billionN/A0.00Upcoming Earnings
Genmab A/S logo
GMAB
Genmab A/S
1.4$37.24+0.4%$24.42 billion$804.57 million28.87Earnings Announcement
Analyst Revision
CureVac logo
CVAC
CureVac
0.7$105.79+5.1%$19.77 billionN/A0.00Gap Up
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.8$86.24+2.0%$19.38 billion$1.30 billion23.56Earnings Announcement
Catalent logo
CTLT
Catalent
1.7$104.80+2.6%$17.85 billion$3.09 billion66.75Earnings Announcement
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$32.24+2.0%$15.24 billion$3.07 billion-56.56Earnings Announcement
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$128.63+2.1%$15.12 billion$219.75 million-16.43
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.39+1.8%$13.96 billion$1.70 billion17.48Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$149.45+5.8%$13.33 billion$12.98 million-49.32
Grifols logo
GRFS
Grifols
1.3$18.60+2.0%$12.79 billion$5.71 billion16.61Earnings Announcement
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.25+1.5%$11.19 billion$16.89 billion-2.79Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.10+0.9%$10.02 billion$2.16 billion55.55Earnings Announcement
Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
2.1$27.53+2.0%$9.87 billion$8.60 billion-5.05Earnings Announcement
Analyst Revision
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.82+3.7%$9.23 billionN/A0.00News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$189.88+2.9%$8.51 billion$1.45 billion17.96Earnings Announcement
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$147.63+2.5%$7.58 billion$3.34 million-19.17Earnings Announcement
Analyst Upgrade
News Coverage
Gap Up
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$109.25+4.8%$7.37 billion$103.71 million-24.89Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$130.07+2.2%$6.99 billion$14.98 million-15.84
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$46.47+3.4%$6.94 billion$40.56 million-13.63Earnings Announcement
Analyst Report
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.10+0.4%$6.88 billion$87.99 million-78.69Earnings Announcement
Analyst Revision
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96+0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$43.12+0.4%$5.76 billion$4.84 billion-718.55Upcoming Earnings
News Coverage
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.03+6.5%$5.59 billion$380.83 million-8.96Earnings Announcement
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.21+2.9%$5.38 billion$66.51 million17.01
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$37.90+6.1%$5.36 billion$150,000.00-17.88Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$36.24+0.8%$5.11 billion$1.12 billion75.50Earnings Announcement
Analyst Upgrade
Allakos logo
ALLK
Allakos
1.7$94.95+6.3%$5.08 billionN/A-34.65News Coverage
Galapagos logo
GLPG
Galapagos
1.3$73.54+2.0%$4.82 billion$1.00 billion-11.14Analyst Report
Gap Down
Schrödinger logo
SDGR
Schrödinger
1.6$64.01+6.8%$4.48 billion$85.54 million0.00Upcoming Earnings
Insider Selling
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.89+0.2%$4.38 billion$6.87 million-7.24Earnings Announcement
Analyst Revision
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$69.34+3.0%$4.30 billionN/A-5.65Earnings Announcement
Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
I-Mab logo
IMAB
I-Mab
1.2$56.74+4.5%$4.08 billion$4.31 million-1.96
LEGN
Legend Biotech
1.3$29.34+2.6%$3.90 billion$64.39 million0.00
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$55.75+0.1%$3.90 billion$117.91 million-11.31
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$63.27+2.4%$3.84 billion$806.43 million-8.96Earnings Announcement
Analyst Report
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$24.99+5.0%$3.72 billion$204.89 million-31.24
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.15+4.3%$3.63 billionN/A-6.08
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.73+1.9%$3.60 billion$114.62 million-7.96Earnings Announcement
Analyst Report
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$21.65+1.7%$3.47 billion$1.17 billion-47.05Insider Selling
High Trading Volume
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.02+0.2%$3.37 billion$339.08 million-12.22Earnings Announcement
Analyst Revision
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$111.76+2.8%$3.29 billionN/A-55.60Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$59.87+2.9%$3.21 billion$1.11 billion19.25
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$62.93+3.2%$3.09 billionN/A-17.93Earnings Announcement
Analyst Revision
News Coverage
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$84.76+0.4%$3.07 billion$26.52 million-7.47Earnings Announcement
Arvinas logo
ARVN
Arvinas
1.7$61.39+3.6%$3.01 billion$42.98 million-23.98Earnings Announcement
Analyst Upgrade
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$35.97+2.6%$2.92 billion$60,000.00-11.17Analyst Revision
News Coverage
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$73.60+2.5%$2.82 billion$644.77 million-10.50News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.90+3.4%$2.74 billion$306.98 million-5.57Earnings Announcement
Analyst Revision
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.